Axsome Therapeutics, Inc. (AXSM) Stock
1 member of Congress disclosed 1 trade in AXSM since 2022: 1 purchase and 0 sales, most recently Christopher L. Jacobs (purchase, Jun 16, 2022). 7 of the hedge funds AlphaScala tracks reported AXSM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $148.03M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Which members of Congress traded Axsome Therapeutics, Inc. (AXSM)?
Most recent: Christopher L. Jacobs (purchase, Jun 16, 2022); records start Jun 16, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Chris Jacobs R-NY · House | 2022-06-16 | purchase | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all AXSM political trades →Which hedge funds own AXSM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 605K | $148.03M | +0% |
| Millennium Management Israel Englander | 556K | $136.11M | +2579% |
| Point72 Steve Cohen | 417K | $101.95M | -2% |
| Renaissance Technologies Jim Simons (founder) | 262K | $64.13M | +59% |
| Citadel Ken Griffin | 256K | $62.63M | -9% |
| Marshall Wace | 223K | $54.68M | +58% |
| Bridgewater Associates Ray Dalio | 58K | $14.25M | +2% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Axsome Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 3, 26 | Jacobson Mark L. | Chief Operating Officer | SELL | 10.0K | $2.1M |
| Aug 6, 26 | Tabuteau Herriot | Chief Executive Officer | SELL | 4.7K | $997K |
| Aug 5, 26 | Tabuteau Herriot | Chief Executive Officer | SELL | 45.0K | $9.5M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →AXSM price chart
Powered by TradingViewWhat does Axsome Therapeutics, Inc. do?
Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of small-molecule medicines and novel therapies targeting central nervous system disorders. The company focuses on conditions with limited treatment options, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome's approach includes fixed-dose combinations and reformulations designed to deliver differentiated therapeutic solutions. The company maintains a pipeline of clinical-stage CNS therapies addressing significant and growing markets. Founded in 2012 and headquartered in New York, New York, Axsome operates as a single business segment dedicated to developing and delivering innovative treatments for patients with underserved CNS conditions. The company has transitioned to commercializing its marketed products while advancing its pipeline of differentiated therapeutic candidates.